COST-EFFECTIVENESS ANALYSIS OF NIRMATRELVIR/RITONAVIR COMPARED WITH MOLNUPIRAVIR IN PATIENTS AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19 IN JAPAN

被引：0
|
作者：
Yuasa, A. [1 ]
Matsuda, H. [2 ]
Fujii, Y. [3 ]
Kado, Y. [2 ]
Murata, K. [1 ]
Yoshida, M. [3 ]
Mugwagwa, T. [4 ]
Gu, Y. [5 ]
机构：
[1] Pfizer Japan Inc, Shibuya Ku, Tokyo, Japan
[2] IQVIA Solut Japan GK, Minato Ku, Tokyo, Japan
[3] Pfizer R&D Japan GK, Shibuya Ku, Tokyo, Japan
[4] Pfizer Inc, New York, NY USA
[5] Tokyo Med & Dent Univ, Bunkyo Ku, Tokyo, Japan
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE180
引用
收藏
页码：S89 / S89
页数：1
相关论文
共 50 条
  • [21] Molnupiravir compared to nirmatrelvir/ritonavir for covid-19 in high-risk patients with haematological malignancy in europe. A matched-paired analysis from the epicovideha registry
    Salmanton-Garcia, J.
    Marchesi, F.
    Koehler, P.
    Weinbergerova, B.
    Colovic, N.
    Falces-Romero, I.
    Glenthoj, A.
    Rahimli, L.
    Cornely, O. A.
    Pagano, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 288 - 288
  • [22] Budget impact of oral nirmatrelvir/ritonavir in adults at high risk for progression to severe COVID-19 in the United States
    Sandin, Rickard
    Veenstra, David L.
    Vankelegom, Mathilde
    Dzingina, Mendwas
    Sullivan, Sean D.
    Campbell, David
    Ma, Cuiying
    Harrison, Cale
    Draica, Florin
    Wiemken, Timothy Lee
    Mugwagwa, Tendai
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (12): : 1290 - 1302
  • [23] Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry
    Salmanton-Garcia, Jon
    Marchesi, Francesco
    Koehler, Philipp
    Weinbergerova, Barbora
    Colovicf, Natasa
    Falces-Romerog, Iker
    Buquicchio, Caterina
    Farinaj, Francesca
    van Praetk, Jens
    Biernat, Monika M.
    Itri, Federico
    Prezioso, Lucia
    Tascini, Carlo
    Vena, Antonio
    Romano, Alessandra
    Delia, Mario
    Davila-Valls, Julio
    Martin-Perez, Sonia
    Lavilla-Rubirat, Esperanza
    Adzic-vukicevicu, Tatjana
    Garcia-Bordallot, Daniel
    Lopez-Garciav, Alberto
    Criscuolo, Mariana
    Petzer, Verena
    Fracchiolla, Nicola S.
    Espigado, Ildefonso
    Sili, Uluhan
    Meers, Stef
    Erben, Nurettin
    Cattaneo, Chiara
    Tragiannidis, Athanasios
    Gavriilaki, Eleni
    Schoenlein, Martin
    Mitrovic, Mirjana
    Pantic, Nikola
    Merelli, Maria
    Labrador, Jorge
    Hernandez-Rivas, Jose-Angel
    Glenthoj, Andreas
    Fouquet, Guillemette
    del Principe, Maria Ilaria
    Dargenio, Michelina
    Calbacho, Maria
    Besson, Caroline
    Kohn, Milena
    Graefe, Stefanie
    Hersby, Ditte Stampe
    Arellano, Elena
    Colakaa, Goekce Melis
    Wolfx, Dominik
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2023, 62 (04)
  • [24] Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease
    Hoertel, Nicolas
    Boulware, David R.
    Sanchez-Rico, Marina
    Burgun, Anita
    Limosin, Frederic
    JAMA NETWORK OPEN, 2022, 5 (11) : e2242140
  • [25] Cost-effectiveness of outpatient COVID-19 antiviral treatment with nirmatrelvir/ritonavir versus usual care in Swedish patients with various risk factors
    Nilsson, Fredrik
    Aldven, Martina
    Rappe, Christian Gerdeskold
    Mugwagwa, Tendai
    JOURNAL OF MEDICAL ECONOMICS, 2025, 28 (01) : 186 - 195
  • [26] Cost-effectiveness analysis of ritonavir boosted nirmatrelvir for adult outpatients with mild to moderate COVID-19 in a European health system
    Wikman-Jorgensen, Philip
    Ibarra, Jose Maria
    Devesa, Carlos
    Peris, Jorge
    Llenas-Garcia, Jara
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2023, 118 : 133 - 135
  • [27] Low antiviral uptake of nirmatrelvir/ ritonavir and molnupiravir in adult patients with COVID-19 in Taiwan in 2022
    Wang, Fu-Der
    Nguyen, Phung-Anh
    Lee, David
    Taysi, Bulent
    d'Hellencourt, Florence Lefebvre
    Spinardi, Julia
    Phuc, Phan Thanh
    Burton, Whitney
    Chang, Yu-Hui
    Hien, Nguyen Thi Kim
    Lin, Shiue-Ming
    Chieh, Yang
    Kyaw, Moe H.
    Hsu, Jason C.
    JOURNAL OF GLOBAL HEALTH, 2024, 14
  • [28] Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19: A meta-regression analysis
    Chen, I-Wen
    Yu, Ting-Sian
    Lin, Chien-Hung
    Hung, Kuo-Chuan
    JOURNAL OF MEDICAL VIROLOGY, 2024, 96 (06)
  • [29] New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19
    Atmar, Robert L.
    Finch, Natalie
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (08)
  • [30] Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
    Lu, Jiayue
    Cai, Hong
    Hao, Yujun
    Lin, Zhang
    Liu, Shang
    Zhan, Yaping
    Ding, Li
    Huang, Meilan
    Li, Zhenyuan
    Xu, Lan
    Yan, Xiujuan
    Yang, Li
    Zhang, He
    Zhang, Wei
    Zhao, Li
    Zhao, Junli
    Wang, Ting
    Gu, Leyi
    FRONTIERS IN PHARMACOLOGY, 2023, 14
12345